<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150851</url>
  </required_header>
  <id_info>
    <org_study_id>100716</org_study_id>
    <nct_id>NCT01150851</nct_id>
  </id_info>
  <brief_title>Oxidative Stress in Chronic Kidney Disease: Diet and Exercise</brief_title>
  <official_title>Oxidative Stress in Chronic Kidney Disease: Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central aim of this study is to improve understanding of how metabolic pathways that&#xD;
      contribute to adiposity also amplify risks of kidney disease progression and cardiovascular&#xD;
      disease in subjects with moderate to severe CKD. In order to achieve this goal, we propose&#xD;
      the following aims through a randomized 2x2 factorial design trial in subjects with moderate&#xD;
      to severe CKD: (a) To assess the feasibility of implementing aerobic exercise and caloric&#xD;
      restriction interventions, and (b) To examine the effects of aerobic exercise and caloric&#xD;
      restriction on a metabolic risk profile, including systemic measures of oxidative stress,&#xD;
      inflammation, insulin resistance, and endothelial dysfunction.&#xD;
&#xD;
      Hypothesis: We hypothesize that implementation of caloric restriction and aerobic exercise is&#xD;
      feasible and can improve the metabolic milieu (as assessed by measures of oxidative stress,&#xD;
      inflammation, insulin resistance, and endothelial dysfunction) in subjects with moderate to&#xD;
      severe CKD.&#xD;
&#xD;
      Interim analysis may be performed (no specific plan at this time).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a change in plasma F-2-isoprostane concentration</measure>
    <time_frame>baseline and 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>a change in VO2 max</measure>
    <time_frame>baseline and 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>a change in weight</measure>
    <time_frame>baseline and 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>a change in absolute fat mass</measure>
    <time_frame>baseline and 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>a change in biomarkers of inflammation</measure>
    <time_frame>baseline and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a change in biomarkers of endothelial dysfunction</measure>
    <time_frame>baseline and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a change in biomarkers of insulin resistance</measure>
    <time_frame>baseline and 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>caloric restriction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aerobic exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>caloric restriction and aerobic exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration, and supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual diet and usual activity</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual diet and usual activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>caloric restriction</intervention_name>
    <description>10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration</description>
    <arm_group_label>caloric restriction</arm_group_label>
    <arm_group_label>caloric restriction and aerobic exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>aerobic exercise</intervention_name>
    <description>supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration</description>
    <arm_group_label>aerobic exercise</arm_group_label>
    <arm_group_label>caloric restriction and aerobic exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage III-IV CKD measured by the MDRD equation with eGFR 15-60 ml/min/1.73m2;&#xD;
&#xD;
          -  Age 18-75 years;&#xD;
&#xD;
          -  BMI ≥ 25;&#xD;
&#xD;
          -  Life expectancy ≥ 1 year;&#xD;
&#xD;
          -  Ability to understand and provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any acute inflammatory condition (including chronic infection requiring treatment, and&#xD;
             collagen vascular disease including active gout);&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Taking high-dose anti-oxidants (Vitamin E or C);&#xD;
&#xD;
          -  Chronic use of anti-inflammatory medication except low dose (&lt; 10mg/d) prednisone and&#xD;
             aspirin (&lt; 100 mg/day);&#xD;
&#xD;
          -  Significant cardiac or vascular disease (symptomatic disease or CV event including&#xD;
             congestive heart failure within 6 months);&#xD;
&#xD;
          -  Significant occlusive atherosclerotic disease or ischemic disease (on non-invasive or&#xD;
             invasive diagnostic procedures);&#xD;
&#xD;
          -  Significant physical immobility or disabilities (joint replacement, muscular&#xD;
             disorders);&#xD;
&#xD;
          -  Type I diabetes mellitus, or Type II requiring insulin therapy;&#xD;
&#xD;
          -  History of poor adherence to medical regimen;&#xD;
&#xD;
          -  Those subjects who have a diagnosis of atrial fibrillation or a pacemaker will be&#xD;
             allowed in the study but will not undergo Arterial Tonometry (PWV) studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alp Ikizler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Himmelfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Springfield College</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01109-3797</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Research Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>June 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Alp Ikizler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

